ArticleDrug design, development and therapy2025
pH-Sensitive Porphyrin Metal-Organic Frameworks for Controlled Delivery of Para-Toluenesulfonamide and Photodynamic Cancer Therapy.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Influence of the Central Metal (Zn) in the Porphyrin Skeleton on the Mechanism Induced by Photodynamic Therapy.Cancers · 2026Review
- Metal Nanoparticles as Sensitizers in Energy-Based Therapies for Lung Cancer: From Mechanistic Insights to Clinical Translation.International journal of nanomedicine · 2026Review
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- High-efficiency encapsulation and pH-triggered release of docetaxel from folic acid-functionalized ZIF-90 nanocarriers.RSC advances · 2025Article
- Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Photodynamic therapy (PDT) is a promising approach for tumor treatment. PDT for treating lung squamous cell carcinoma (LSCC) under the guidance of bronchoscopy has great potential for development. However, the use of high-intensity lasers in treatment may pose a risk of tissue damage. To address this issue, enhancing the sensitivity of tumor tissue to phototherapy is highly valuable. Methods: In this study, a simple method was employed to prepare porphyrin-metal framework nanoparticles (NPs), referred to as HA-PTS@PCN. The design of these NPs is based on the concept of tumor sensitization, constructed with the porphyrin-based metal-organic framework compound PCN-224 to load the drug para-toluenesulfonamide (PTS). Results: Multiple experiments have demonstrated that these NPs can be effectively absorbed and selectively release PTS within the acidic tumor microenvironment. Under 660 nm laser irradiation, the material releases reactive oxygen species, demonstrating effective photodynamic therapeutic effects. Additionally, due to the tumor-sensitizing properties of PTS, the treatment efficacy of these NPs on LSCC is significantly greater than that of PCN-224 alone. Both in vitro and in vivo studies confirmed that combining tumor sensitization strategies with PDT therapy for LSCC significantly enhances anticancer effects. Discussion: This study provides a universal strategy for preparing drug-loaded PDT nanoplatforms and offers a new approach for developing nanomedicine with tumor-sensitizing effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.